Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Shilajit and ghee, ancient Ayurvedic components, form a potent blend with numerous health benefits. Shilajit and ghee together make a powerful Ayurvedic supplement that can help improve energy ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived and died” on the outlook for Alzheimer’s ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Revenue: US$9.68b (down 1.6% from FY 2023). Net income: US$1.63b (up 41% from FY 2023). Profit margin: 17% (up from 12% in FY 2023). The increase in margin was driven by lower expenses. EPS: US$11 ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.